paroxysmal nocturnal hemoglobinuria (PNH) | Page 16 | Aplastic Anemia & MDS International Foundation

paroxysmal nocturnal hemoglobinuria (PNH)

Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria

Author(s): 
Hillmen P, Muus P, Szer J, Hill A, Höchsmann B, Kulasekararaj A, Risitano AM, Van Den Neste E, Liljeholm M, Ebrahim KS, Bedrosian CL, Gao X, Ames D, Socié G
Primary Author: 
Hillmen P
Journal Title: 
Am J Hematol
Original Publication Date: 
Dec 2015

No abstract available.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare bone marrow failure disease in which red blood cells break apart. Normal red blood cells have a shield of proteins that protect them from coming under attack by the body's own immune system. PNH occurs because that protein shield is missing. PNH is often associated with reduced bone marrow function (low blood counts) caused by aplastic anemia.

Phil Scheinberg, MD

Scheinberg, Phil
Chief of Clinical Hematology
Hospital Sao Jose, Beneficencia Portuguesa de Sao Paolo

Dr. Phil Scheinberg is Chief of Clinical Hematology at the Hospital Sao Jose, Beneficencia Portuguesa de Sao Paolo in Brazil. He received his medical degree in 1995 at the University of Santo Amaro in Sao Paulo, Brazil and completed his residency (1997-2001) at Mount Sinai Medical Center in Miami Beach, FL where he became Medical Chief Resident. Dr. Scheinberg held a Hematology/Oncology Fellowship (2001-2005) before becoming a staff clinician at the Hematology Branch of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, MD.